Impact of poisonous snake bite on the health status by understanding the changes happening after the bite.

Understanding the pathophysiology of snake bite associated thrombotic microangiopathy

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2019/07/020006

Enrollment

Registered

2019-07-02

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: T630- Toxic effect of snake venom

Interventions

Control Intervention1: ADAMTS 13, Factor H and microparticles in patients without thrombotic microangiopathy: Hematotoxic snake bite patients often have isolated coagulopathy without systemic envenoma

Eligibility

Inclusion criteria

Inclusion criteria: 1. Hematotoxic snake bites 2. Specified age group 3. Patients admitted on the day of bite

Exclusion criteria

Exclusion criteria: 1. Patients who do not want to participate in the study. 2. Patients who are discharged after 48 hours or who obtain discharge against medical advices. 3. Pregnant females. 4. Patients who are diagnosed cases of bleeding disorders or on anti platelet drugs and oral anticoagulant 5. Treated outside hospitals

Design outcomes

Primary

Measure	Time frame
1. Analysis of the serum ADMATS 13 level and Complement Factor H activity to understand the pathophysiology of TMA in these patients. 2. Comparison of cellular microparticle concentration between the two groups to understand the clinical implications of these microparticles in snakebite associated TMA. 3. Establishing the correlation between these parameters and the clinical outcome of the patient whether they a play any role on patientÃ¢â?¬â?¢s prognosis.Timepoint: A) 0-6 months - Establishing the Flow cytometry and ELISA tests. B) 6 months to 36 months - Enrolling of patients and sample collections and clinical monitoring. C) 6months to 36 months - Flow cytometry analysis of cell derived microparticles. D) 24 months to 36 months - ELISA testing for ADAMTS 13, Complement Factor H proteins. E) 30 months - 36 months - Data analysis and manuscript completion	—

Measure

Time frame

1. Analysis of the serum ADMATS 13 level and Complement Factor H activity to understand the pathophysiology of TMA in these patients. 2. Comparison of cellular microparticle concentration between the two groups to understand the clinical implications of these microparticles in snakebite associated TMA. 3. Establishing the correlation between these parameters and the clinical outcome of the patient whether they a play any role on patientÃ¢â?¬â?¢s prognosis.Timepoint: A) 0-6 months - Establishing the Flow cytometry and ELISA tests. B) 6 months to 36 months - Enrolling of patients and sample collections and clinical monitoring. C) 6months to 36 months - Flow cytometry analysis of cell derived microparticles. D) 24 months to 36 months - ELISA testing for ADAMTS 13, Complement Factor H proteins. E) 30 months - 36 months - Data analysis and manuscript completion

—

Secondary

Measure	Time frame
1. Effect of TMA on the prognosis will be assessed by the length of hospital stay, interventions like hemodialysis and blood transfusion received, complications and 30 days mortality. 2. Complication rates across both the groups will be analysed to identify the role of TMA in the clinical course of the disease.Timepoint: 6months - 30 months	—

Countries

India

Contacts

Public ContactGanesh Mohan

Kasturba Medical College

drganeshmohan@gmail.com9539788828

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026